Test my supply
+1 more ↓
59%
Finnrick rating
#275 of 301 ranked vendors
47 of 70 classifiable tests passed
methodology · Purity focus
Finnrick analysis

HkRoids' purity-focused record is strongest on GHK-Cu and BPC-157, where identity and purity are steady but fill swings still appear. Results are dispersed: Retatrutide and Tirzepatide carry repeated purity or severe quantity misses, while CJC-1295 adds a recent identity/0 mg failure amid uneven batch documentation.

methodology →
vendor intelligence report
Vendor Intelligence Report: HkRoids

Wayback captures tie HkRoids to a China-linked raw-steroid exporter, while current records do not substantiate a US operating entity. The report follows the rep network, payment rails, defunct sister domains, and a Tirzepatide identity dispute.

26 pages7 risk factors assessed2 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.08
92%
7
2
Retatrutide
$1.36
75%
15
3
Tirzepatide
$0.50
74%
12
4
BPC-157
$0.94
69%
9
5
Ipamorelin
$0.94
68%
6
6
Tesamorelin
$2.58
50%
9
7
MOTS-c
$0.79
35%
4
8
CJC-1295
$2.35
32%
5
9
KPV
$0.82
25%
4
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%1 Mar 2026: 64%3 Mar 2026: 64%3 Mar 2026: 64%3 Mar 2026: 64%12 Mar 2026: 65%12 Mar 2026: 65%13 Mar 2026: 65%16 Mar 2026: 64%18 Mar 2026: 65%21 Mar 2026: 66%25 Mar 2026: 70%25 Mar 2026: 70%25 Mar 2026: 70%15 Apr 2026: 70%21 Apr 2026: 70%21 Apr 2026: 69%28 Apr 2026: 63%8 May 2026: 63%13 May 2026: 63%27 May 2026: 63%27 May 2026: 63%27 May 2026: 64%31 May 2026: 57%1 Jun 2026: 62%1 Jun 2026: 63%1 Jun 2026: 63%1 Jun 2026: 63%1 Jun 2026: 63%1 Jun 2026: 63%1 Jun 2026: 64%26 Jun 2026: 64%9 Jul 2026: 64%14 Jul 2026: 62%14 Jul 2026: 61%20 Jul 2026: 60%20 Jul 2026: 60%20 Jul 2026: 60%20 Jul 2026: 60%20 Jul 2026: 60%23 Jul 2026: 60%10 Aug 2026: current 59%64%63%59%Mar 26Aug 26
Test my supply
HkRoids test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
23 Jul 2026Fail
BPC-157
lab nameView COA
20 Jul 2026Pass
Tirzepatide
lab nameView COA
20 Jul 2026Fail
KPV
lab nameView COA
20 Jul 2026Fail
Tesamorelin
lab nameView COA
20 Jul 2026Pass
Tirzepatide
lab nameView COA
20 Jul 2026Pass
Retatrutide
lab nameView COA
14 Jul 2026Fail
MOTS-c
lab nameView COA
14 Jul 2026Fail
KPV
lab nameView COA
9 Jul 2026Pass
Tirzepatide
lab nameView COA
26 Jun 2026Pass
GHK-Cu
lab nameView COA
1-10 of 71

About HkRoids test results from Finnrick

HkRoids is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 9 peptides and 71 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible HkRoids peptides in this dataset are BPC-157 (9 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 71 recent tests.

Corrections
No corrections.
Test my supply